Business
Atai is a clinical-stage biopharmaceutical company developing mental-health treatments, including in-house and invested pipeline programs.
Atai revenue was only $308K, net loss widened to $149.3M, and FCF burn stayed high despite a large insider buy.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage mental-health biopharmaNote
- Revenue — Revenue was $308KWatch
- Losses — Net loss widened to $149.3MWatch
- Cash — FCF was -$82.4MWatch
- Balance sheet — Equity fell 52.1%Watch
- Insiders — 1 buy / 0 sells; $19.0M valueOK
- Accounting — Altman-Z distressWatch
Where the revenue comes from
Fiscal 2025, as AtaiBeckley Inc. reports it. History and quarterly detail are in the app.
- Research And Development Services Revenue$3.9M
- License$202K
Leadership changes
From AtaiBeckley Inc.'s own filings, the day they're filed.
- Michael Faerm · Chief Financial Officer · appointmenteff. 2026-02-15
- Cosmo Feilding-Mellen · directors · departureeff. 2026-01-06
Latest filings
- 8-K · Company announcement2026-08-31
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-06-08
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AtaiBeckley Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.